Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.040 HKD
−418.61 M HKD
113.67 M HKD
382.98 M
About CANBRIDGE PHARMACEUTICALS INC
Sector
CEO
James Xue
Headquarters
Beijing
Website
Founded
2012
FIGI
BBG013TKDNH3
CANbridge Pharmaceuticals Inc. operates as a rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies. The firm's pipeline and products include rare oncology, rare diseases, gene theraphy, Huntercase, Nerlynx, and Caphosol. It operates through the following geographical segment: Mainland China, Taiwan, and Hong Kong. The company was founded by James Xue in 2012 and is headquartered in Beijing, China.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 1228 is 0.210 HKD — it hasn't changed in the past 24 hours. Watch CANBRIDGE PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange CANBRIDGE PHARMACEUTICALS INC stocks are traded under the ticker 1228.
1228 stock has fallen by −7.20% compared to the previous week, the month change is a −23.16% fall, over the last year CANBRIDGE PHARMACEUTICALS INC has showed a −83.97% decrease.
1228 reached its all-time high on Dec 10, 2021 with the price of 9.990 HKD, and its all-time low was 0.187 HKD and was reached on Aug 6, 2024. View more price dynamics on 1228 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
1228 stock is 6.83% volatile and has beta coefficient of 1.81. Track CANBRIDGE PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is CANBRIDGE PHARMACEUTICALS INC there?
Today CANBRIDGE PHARMACEUTICALS INC has the market capitalization of 99.84 M, it has decreased by −7.69% over the last week.
Yes, you can track CANBRIDGE PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
CANBRIDGE PHARMACEUTICALS INC is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
1228 net income for the last half-year is −267.95 M HKD, while the previous report showed −173.58 M HKD of net income which accounts for −54.36% change. Track more CANBRIDGE PHARMACEUTICALS INC financial stats to get the full picture.
No, 1228 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 14, 2024, the company has 100.00 employees. See our rating of the largest employees — is CANBRIDGE PHARMACEUTICALS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CANBRIDGE PHARMACEUTICALS INC EBITDA is −379.76 M HKD, and current EBITDA margin is −328.65%. See more stats in CANBRIDGE PHARMACEUTICALS INC financial statements.
Like other stocks, 1228 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CANBRIDGE PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CANBRIDGE PHARMACEUTICALS INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CANBRIDGE PHARMACEUTICALS INC stock shows the sell signal. See more of CANBRIDGE PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.